M Holdings Securities Inc. Takes Position in Moderna, Inc. (NASDAQ:MRNA)

M Holdings Securities Inc. acquired a new stake in shares of Moderna, Inc. (NASDAQ:MRNAGet Rating) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 2,498 shares of the company’s stock, valued at approximately $430,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Advisory Services Network LLC increased its holdings in shares of Moderna by 27.4% during the first quarter. Advisory Services Network LLC now owns 4,602 shares of the company’s stock valued at $793,000 after acquiring an additional 990 shares in the last quarter. Aurora Investment Counsel increased its holdings in shares of Moderna by 21.0% during the first quarter. Aurora Investment Counsel now owns 7,031 shares of the company’s stock valued at $1,211,000 after acquiring an additional 1,221 shares in the last quarter. Neuberger Berman Group LLC increased its holdings in shares of Moderna by 5.1% during the first quarter. Neuberger Berman Group LLC now owns 33,740 shares of the company’s stock valued at $5,819,000 after acquiring an additional 1,649 shares in the last quarter. The Manufacturers Life Insurance Company increased its holdings in shares of Moderna by 1.6% during the first quarter. The Manufacturers Life Insurance Company now owns 2,215,455 shares of the company’s stock valued at $381,789,000 after acquiring an additional 34,636 shares in the last quarter. Finally, Resources Management Corp CT ADV grew its holdings in Moderna by 12.4% during the first quarter. Resources Management Corp CT ADV now owns 1,098 shares of the company’s stock worth $189,000 after buying an additional 121 shares in the last quarter. Institutional investors own 60.76% of the company’s stock.

Insiders Place Their Bets

In other news, CFO David W. Meline sold 164 shares of the business’s stock in a transaction that occurred on Wednesday, August 10th. The shares were sold at an average price of $173.66, for a total value of $28,480.24. Following the sale, the chief financial officer now owns 2,857 shares of the company’s stock, valued at $496,146.62. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other news, CFO David W. Meline sold 164 shares of the business’s stock in a transaction that occurred on Wednesday, August 10th. The shares were sold at an average price of $173.66, for a total value of $28,480.24. Following the sale, the chief financial officer now owns 2,857 shares of the company’s stock, valued at $496,146.62. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Noubar Afeyan sold 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, June 22nd. The shares were sold at an average price of $127.69, for a total transaction of $1,276,900.00. Following the completion of the sale, the director now directly owns 2,527,209 shares in the company, valued at approximately $322,699,317.21. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 653,048 shares of company stock valued at $102,324,342. Company insiders own 17.30% of the company’s stock.

Moderna Stock Performance

Shares of MRNA stock opened at $137.74 on Friday. The firm has a market cap of $54.79 billion, a price-to-earnings ratio of 4.20, a P/E/G ratio of 0.81 and a beta of 1.69. The company has a debt-to-equity ratio of 0.04, a quick ratio of 1.71 and a current ratio of 1.99. Moderna, Inc. has a 52 week low of $115.61 and a 52 week high of $458.50. The firm’s 50-day simple moving average is $156.09 and its two-hundred day simple moving average is $151.07.

Moderna (NASDAQ:MRNAGet Rating) last announced its quarterly earnings data on Wednesday, August 3rd. The company reported $5.24 EPS for the quarter, topping the consensus estimate of $4.73 by $0.51. The business had revenue of $4.73 billion for the quarter, compared to analyst estimates of $3.95 billion. Moderna had a net margin of 61.12% and a return on equity of 94.76%. The company’s revenue for the quarter was up 8.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted $6.46 earnings per share. As a group, equities analysts forecast that Moderna, Inc. will post 26.41 earnings per share for the current year.

Analyst Upgrades and Downgrades

MRNA has been the subject of several recent research reports. Deutsche Bank Aktiengesellschaft upgraded Moderna from a “hold” rating to a “buy” rating and upped their price target for the stock from $155.00 to $165.00 in a report on Wednesday, September 7th. Morgan Stanley decreased their price target on Moderna from $199.00 to $197.00 and set an “equal weight” rating for the company in a report on Thursday, August 4th. SVB Leerink upped their price target on Moderna from $70.00 to $77.00 and gave the stock an “underperform” rating in a report on Monday, August 1st. Finally, Argus decreased their price target on Moderna from $180.00 to $150.00 and set a “buy” rating for the company in a report on Wednesday. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $211.08.

Moderna Company Profile

(Get Rating)

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines.

Read More

Institutional Ownership by Quarter for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.